FN2 Earnings Intelligence
COO revenue earnings history
The Cooper Companies, Inc. (COO) quarterly reported and estimated revenue history by fiscal quarter.
Earnings History
The Cooper Companies, Inc.
The quarter supports a cautiously constructive operating thesis: demand appears resilient in key franchises, but reported vision revenue is temporarily constrained by U.S. inventory reduction and the next phase depends on execution in APAC, product launches, and fertility growth.
The Cooper Companies, Inc.
Cooper Companies delivered its tenth consecutive consensus beat with record Q2 revenue of $1.08 billion (up 8% YoY) and non-GAAP EPS of $1.21 (up 26% YoY), driven by premium silicone hydrogel lens demand and fertility capital equipment strength. The stock surged 8.6% on the report with continued positive drift of 6.8% over subsequent sessions. Two major strategic developments reshape the company's forward profile: a $271.6 million settlement of the embryo culture media litigation covering over 95% of claimants, and the launch of a strategic review of the entire CooperSurgical segment with multiple interested parties. Management maintained full-year guidance despite a softer Asia-Pacific outlook while raising the free cash flow outlook to approximately $650 million, supported by AI-driven inventory optimization.
The Cooper Companies, Inc.
The latest analysis supports a constructive but qualified view: MyDay-led share gains, fertility initiatives, operating efficiencies, and higher free-cash-flow targets strengthen the growth case, while APAC weakness, margin pressure, PARAGARD competition, and strategic-review uncertainty temper it.
The Cooper Companies, Inc.
The supplied analysis supports a cautiously constructive view of Cooper Companies' operating trajectory: MyDay launches, private-label contracts, MiSight expansion and lower capital intensity may support growth and cash flow, but Clarity softness, pricing pressure, PARAGARD declines and regulatory execution remain material offsets.
The Cooper Companies, Inc.
The quarter supports a constructive but qualified view: demand for MyDay and MySite, added capacity, and private-label growth provide operating support, while China weakness, inventory risks, competition, and currency remain important offsets.
The Cooper Companies, Inc.
The supplied analysis supports a constructive but conditional view: resilient demand in daily lenses, myopia management, and fertility products provides growth support, while supply constraints, PARAGARD competition, regional softness, FX, and a lower-than-expected guidance range temper the outlook.
The Cooper Companies, Inc.
The quarter supports a constructive growth case: demand for daily lenses and myopia-management products remained strong, fertility recovered, and management raised FY2024 guidance. The key test is whether added capacity and pricing can convert demand into sustained growth without worsening supply, rebate, recall or competitive risks.
Get the COO recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.